Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 23, 1997

View Archived Issues

Cell adhesion inhibitors claimed by Nippon Shinyaku

Toyama discloses antiplatelet agents

ACAT inhibitors from Takeda

SmithKline Beecham reports new antiinflammatory/antiallergic agents

New COX-2 inhibitor series disclosed by Merck Frosst

5-HT3/5-HT4 receptor ligands disclosed by Synthelabo

New antiasthma agents from Tanabe Seiyaku

NIH continues pivotal HIV-IG trial

Neurex compound headed for pivotal trials in head trauma

Glaxo Wellcome claims new formulation of anxiolytic agent

Almirall and Prodesfarma heading for merger

Panax and Sangen to combine

Raloxifene for inhibition of vascular smooth muscle cell migration

Smoking definitively linked to cardiovascular morbidity and mortality

MAb from Hayashibara with IFN-inducing properties

Clinical results of gabapentin in ALS reported

Inhibitors of alpha-amylase disclosed by Japanese researchers

Eisai discloses IL-1 inhibitors

Connective Therapeutics advances development of interferon

BMS cognition enhancer not superior to placebo in clinical study

New AMPA receptor modulator described by Servier

TBC receives patent coverage for endothelin antagonists

New tool for studying phosphodiesterase receptors

FDA expands orphan drug designation for NTZ

Labopharm and Sepracor to develop solid oral form of levalbuterol

ID Biomedical developing TB test

NIH offers licenses for conjugate vaccine

NIH seeks licensees for dopamine reuptake inhibitors

NIH offers licenses for IDDM markers

NIH seeks licensees for perilipins

Collaborators sought for gene therapy technology

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...